Compare OI & VCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OI | VCEL |
|---|---|---|
| Founded | 1903 | 1989 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Containers/Packaging | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 2.0B |
| IPO Year | N/A | 1997 |
| Metric | OI | VCEL |
|---|---|---|
| Price | $15.40 | $37.36 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 5 |
| Target Price | $17.43 | ★ $57.50 |
| AVG Volume (30 Days) | ★ 2.3M | 586.8K |
| Earning Date | 02-10-2026 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 236.54 |
| EPS | N/A | ★ 0.25 |
| Revenue | ★ $6,455,000,000.00 | $258,716,999.00 |
| Revenue This Year | $1.41 | $17.86 |
| Revenue Next Year | $1.99 | $18.55 |
| P/E Ratio | ★ N/A | $151.65 |
| Revenue Growth | N/A | ★ 14.05 |
| 52 Week Low | $9.23 | $29.24 |
| 52 Week High | $16.04 | $63.00 |
| Indicator | OI | VCEL |
|---|---|---|
| Relative Strength Index (RSI) | 55.84 | 48.73 |
| Support Level | $14.95 | $35.99 |
| Resistance Level | $16.03 | $41.65 |
| Average True Range (ATR) | 0.45 | 1.75 |
| MACD | -0.02 | -0.01 |
| Stochastic Oscillator | 52.24 | 32.12 |
O-I Glass is the world's largest manufacturer of glass bottles; 70% of its revenue comes from outside the United States. O-I has a leading position in key markets such as Europe, North America, and Brazil. Beer is the primary end market for O-I's glass bottles, which are also used for wine, soda, spirits, condiments, and food. O-I is looking to maintain or expand its dominant positions in Europe, North America, and South America.
Vericel Corp is a fully integrated, commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.